A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Summary

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

Timeline

Start

2024-04-01

Primary completion

2027-01-16

Completion

2027-01-27

Drugs

Indications